AR023482A1 - NUCLEIC ACIDS CODING CHEMICAL POLYPEPTIDES CD40 / CD4OL, METHODS FOR THEIR PRODUCTION AND USES OF THE SAME - Google Patents
NUCLEIC ACIDS CODING CHEMICAL POLYPEPTIDES CD40 / CD4OL, METHODS FOR THEIR PRODUCTION AND USES OF THE SAMEInfo
- Publication number
- AR023482A1 AR023482A1 ARP000101716A ARP000101716A AR023482A1 AR 023482 A1 AR023482 A1 AR 023482A1 AR P000101716 A ARP000101716 A AR P000101716A AR P000101716 A ARP000101716 A AR P000101716A AR 023482 A1 AR023482 A1 AR 023482A1
- Authority
- AR
- Argentina
- Prior art keywords
- cd4ol
- production
- methods
- nucleic acids
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Abstract
Un ácido nucleico que codifica un polipéptido quimérico que comprende fragmentos de ácido nucleico que codifican: i) un péptido senal mamífero, ycorriente abajo del mismo: ii) el dominio de vinculacion y de trimerizacion del CD40L, y, corriente abajodel mismo: iii) un separador de 50 a 100 amino ácidosy, corriente abajo del mismo: iv) los dominios transmembranal y de transduccion de las senales, del CD40, es util como agente de terapia de genes para eltratamiento localizado de los tumores solidos.A nucleic acid encoding a chimeric polypeptide comprising nucleic acid fragments encoding: i) a mammalian signal peptide, and downstream thereof: ii) the binding and trimerization domain of CD40L, and, downstream thereof: iii) a 50 to 100 amino acid separator and downstream thereof: iv) the transmembrane and signal transduction domains of CD40 are useful as a gene therapy agent for the localized treatment of solid tumors.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99107611A EP1067194A1 (en) | 1999-04-16 | 1999-04-16 | Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof |
| EP99113967 | 1999-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR023482A1 true AR023482A1 (en) | 2002-09-04 |
Family
ID=26152970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000101716A AR023482A1 (en) | 1999-04-16 | 2000-04-13 | NUCLEIC ACIDS CODING CHEMICAL POLYPEPTIDES CD40 / CD4OL, METHODS FOR THEIR PRODUCTION AND USES OF THE SAME |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1173589A1 (en) |
| JP (1) | JP2003508016A (en) |
| AR (1) | AR023482A1 (en) |
| AU (1) | AU3966200A (en) |
| CA (1) | CA2369820A1 (en) |
| IL (1) | IL144952A0 (en) |
| NO (1) | NO20015003L (en) |
| WO (1) | WO2000063395A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60143535D1 (en) | 2000-10-02 | 2011-01-05 | Novartis Vaccines & Diagnostic | HUMAN ANTIBODIES AGAINST CD40 |
| WO2002036769A2 (en) * | 2000-10-31 | 2002-05-10 | F. Hoffmann-La Roche Ag | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| EP2301575A1 (en) | 2003-11-04 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Methods of therapy for solid tumors expressing the CD40 cell-surface antigen |
| EP1694360B1 (en) | 2003-11-04 | 2010-08-04 | Novartis Vaccines and Diagnostics, Inc. | Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection |
| WO2005044304A2 (en) | 2003-11-04 | 2005-05-19 | Chiron Corporation | Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia |
| EP2236172A1 (en) | 2003-11-04 | 2010-10-06 | Novartis Vaccines and Diagnostics, Inc. | Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers |
| ES2346978T3 (en) | 2003-11-04 | 2010-10-22 | Novartis Vaccines And Diagnostics, Inc. | USE OF ANTI-CD40 ANTIGONIST MONOCLONANT ANTIBODIES FOR THE TREATMENT OF MULTIPLE MYELOMA. |
| JP5421590B2 (en) | 2005-05-18 | 2014-02-19 | ノバルティス アーゲー | Methods for diagnosis and treatment of diseases with autoimmune and / or inflammatory components |
| EA018301B1 (en) | 2006-04-21 | 2013-07-30 | Новартис Аг | Pharmaceutical compositions comprising antagonist monoclonal anti-cd40 antibody and use thereof |
| EP2517723B1 (en) | 2006-09-18 | 2019-11-06 | The Board of Trustees of The University of Arkansas | Compositions and methods of enhancing immune responses |
| BRPI0818736A2 (en) | 2007-10-30 | 2017-06-13 | Univ Arkansas | compositions and methods for enhancing immunoresponders to flagellated bacteria |
| HUE047164T2 (en) | 2007-11-01 | 2020-04-28 | Univ Arkansas | Compositions and methods of enhancing immune responses to eimeria |
| JP5568807B2 (en) * | 2008-06-06 | 2014-08-13 | 静岡県 | Identification of melanoma markers using proteomic analysis |
| EP2525817B8 (en) | 2010-01-21 | 2017-09-20 | The Board of Trustees of The University of Arkansas | Vaccine vectors and methods of enhancing immune responses |
| HUE046858T2 (en) | 2010-06-09 | 2020-03-30 | Univ Arkansas | Vaccine and methods to reduce campylobacter infection |
| WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
| MY173328A (en) | 2013-02-14 | 2020-01-16 | Texas A & M Univ Sys | Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection |
| EA033538B1 (en) | 2013-03-15 | 2019-10-31 | Univ Arkansas | Compositions and methods of enhancing immune responses to enteric pathogens |
| TWI758288B (en) | 2016-05-03 | 2022-03-21 | 阿肯色州大學董事會 | Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same |
| AU2017362730B2 (en) * | 2016-11-21 | 2021-04-08 | Nant Holdings Ip, Llc | Fractal combination therapy |
| US20200024326A1 (en) * | 2018-06-14 | 2020-01-23 | Nantbio, Inc. | Tnf-type receptor-ligand fusion proteins and methods |
| CN113056479A (en) * | 2018-10-05 | 2021-06-29 | 南特细胞公司 | CD40 and CD40L conjugates in an adenoviral vaccine vehicle |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3308534B2 (en) * | 1991-10-25 | 2002-07-29 | イミュネックス・コーポレーション | New cytokine |
| US5716805A (en) * | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
| US7070771B1 (en) * | 1996-12-09 | 2006-07-04 | Regents Of The University Of California | Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells |
-
2000
- 2000-04-13 EP EP00918873A patent/EP1173589A1/en not_active Withdrawn
- 2000-04-13 IL IL14495200A patent/IL144952A0/en unknown
- 2000-04-13 AU AU39662/00A patent/AU3966200A/en not_active Abandoned
- 2000-04-13 JP JP2000612474A patent/JP2003508016A/en active Pending
- 2000-04-13 WO PCT/EP2000/003318 patent/WO2000063395A1/en not_active Application Discontinuation
- 2000-04-13 CA CA002369820A patent/CA2369820A1/en not_active Abandoned
- 2000-04-13 AR ARP000101716A patent/AR023482A1/en unknown
-
2001
- 2001-10-15 NO NO20015003A patent/NO20015003L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1173589A1 (en) | 2002-01-23 |
| WO2000063395A1 (en) | 2000-10-26 |
| JP2003508016A (en) | 2003-03-04 |
| AU3966200A (en) | 2000-11-02 |
| IL144952A0 (en) | 2002-06-30 |
| NO20015003D0 (en) | 2001-10-15 |
| CA2369820A1 (en) | 2000-10-26 |
| NO20015003L (en) | 2001-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR023482A1 (en) | NUCLEIC ACIDS CODING CHEMICAL POLYPEPTIDES CD40 / CD4OL, METHODS FOR THEIR PRODUCTION AND USES OF THE SAME | |
| ATE352626T1 (en) | POLYPEPTIDES WITH GALACTOSE OXIDASE ACTIVITY AND NUCLEIC ACIDS CODING THEREFOR | |
| WO2002031134A3 (en) | Novel serine protease genes related to dppiv | |
| ES2046177T3 (en) | CONSTRUCTION OF A BINDING PROTEIN TO IGG TO FACILITATE THE TREATMENT OF WATER BELOW USING PROTEIN ENGINEERING. | |
| DE3880739D1 (en) | EXPRESSION OF HUMAN PROAPOLIPOPROTEIN A-1. | |
| ATE319818T1 (en) | POLYPEPTIDES WITH AMINOOPEPTIDASE ACTIVITY AND NUCLEIC ACIDS ENCODING THEM | |
| DK0559884T4 (en) | Recombinant viral vectors for expression in muscle cells | |
| BR9913331A (en) | Expression and export of angiogenesis inhibitors as immunofusins | |
| ATE444361T1 (en) | IL-17 AND IL-17R HOMOLOGUE POLYPEPTIDES AND THERAPEUTIC USES | |
| WO2002036769A3 (en) | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof | |
| WO1998031818A3 (en) | Tace-like and matrilysin-like polypeptides | |
| BR9814404A (en) | "expression cloning in filamentous fungi" | |
| ATE414775T1 (en) | POLYPEPTIDES WITH PROLYLDIPEPTIDYLAMINOPEPTIDASE ACTIVITY AND NUCLEIC ACIDS CODING THEREFOR | |
| DE69738370D1 (en) | MODULATORS OF THE TNF RECEPTOR ASSOCIATED FACTOR, THEIR PREPARATION AND USES | |
| ATE450603T1 (en) | POLYPEPTIDES WITH BRANCHING ENZYME ACTIVITY AND NUCLEIC ACIDS ENCODING THEM | |
| DE69942861D1 (en) | LDCAM CALLED MOLECULES | |
| Kim et al. | Construction of chimeric human epidermal growth factor containing short collagen-binding domain moieties for use as a wound tissue healing agent | |
| DE69837475D1 (en) | POLYPEPTIDES WITH AMINOOPEPTIDASE ACTIVITY AND NUCLEIC ACIDS THEREFOR | |
| WO1998011234A3 (en) | Human protein kinases | |
| DE69837265D1 (en) | POLYPEPTIDES FOR REGENERATING THE NERVOUS SYSTEM | |
| ATE288491T1 (en) | POLYPEPTIDES WITH 5-AMINOLEVULIC ACID SYNTHASE ACTIVITY AND THEIR NUCLEIC ACIDS | |
| DE60027928D1 (en) | HUMAN, CERTAIN CANCER-SPECIFIC SUPPRESSOR PROTEIN, PROTEIN CODING POLYNUCLEOTIDE, CELL TRANSFORMED WITH THE POLYNUCLEOTIDE, AND METHODS OF SUPPRESSING THE PROLIFERATION OF CANCER CELLS USING THE EXPRESSION VECTOR | |
| DE60026049D1 (en) | POLYPEPTIDES WITH GLUCANOTRANSFERASE ACTIVITY AND NUCLEIC ACIDS CODING THEREFOR | |
| MX9806628A (en) | Novel human myeloid terminal differentiation response gene | |
| WO2000026340A3 (en) | Novel nucleic acid molecules encoding opioid growth factor receptors |